Subscribe To
Travere therapeutics announces late-breaking data from phase 3 studies of sparsentan in igan and fsgs published in the lancet and the nejm respectively and presented at the american society of nephrol
Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan...
November 3, 2023, 2:46 pm
Travere therapeutics to present abstracts at the american society of nephrology (asn) kidney week 2023
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI® (sparsentan...
October 13, 2023, 8:30 pm
Travere therapeutics to present abstracts at the american society of nephrology (asn) kidney week 2023
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI ® (sparsentan...
October 13, 2023, 4:30 pm
Travere therapeutics to present abstracts at the 17th international symposium on iga nephropathy (iigann 2023)
SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will pr...
September 26, 2023, 4:30 pm
Travere therapeutics stock slides 35% after announcing disappointing results from 2-year trial of kidney drug
Travere Therapeutics Inc.'s stock TVTX tumbled 35% Tuesday, after the company said data from a two-year study of a kidney drug failed to show a statis...
May 2, 2023, 12:50 pm
Travere therapeutics announces topline results from two-year primary efficacy endpoint in pivotal phase 3 duplex study of sparsentan in focal segmental glomerulosclerosis
The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints tren...
May 1, 2023, 8:05 pm
Travere therapeutics announces interim analysis from the phase 3 protect study of filspari™ (sparsentan) in iga nephropathy published in the lancet and presented at world congress of nephrology 2023
FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control SAN DIEGO, April 01, 202...
April 1, 2023, 8:30 am
Chinook: travere's sparsentan approval is net positive
Travere's FILSPARI (sparsentan) received accelerated approval for IgAN's disease on Feb 17, 2023. Chino...
February 22, 2023, 2:26 am
Travere: multiple catalysts stacking
There are other powerful catalysts brewing in the pipeline that would deliver leaping sales growth in the coming years. ...
February 14, 2023, 9:54 am
Travere: sparsentan approval is likely, but future is uncertain
IgA Nephropathy (IgAN) is a chronic autoimmune disease that affects the kidneys and leads to end-stage kidney disease. Current treatments for IgAN are...
February 13, 2023, 5:23 pm
Travere therapeutics: upcoming 'pdufa' date for kidney disease therapy is critical
Travere Therapeutics, Inc. is set to find out on Feb 17th whether the FDA has granted accelerated approval to lead drug candidate ...
January 26, 2023, 12:05 pm